Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden
· Delayed Price · Currency is SEK 6.08
+0.18 (3.09%)
Mar 10, 2026, 9:19 AM CET
Xbrane Biopharma AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 86.59 | 124.33 | 65.4 | 193.99 | 295.18 | Upgrade
|
| Cash & Short-Term Investments | 86.59 | 124.33 | 65.4 | 193.99 | 295.18 | Upgrade
|
| Cash Growth | -30.36% | 90.10% | -66.29% | -34.28% | 21.40% | Upgrade
|
| Accounts Receivable | 6.74 | 16.85 | - | 1.34 | - | Upgrade
|
| Other Receivables | 5.56 | 76.01 | 71.18 | 46.12 | 108.3 | Upgrade
|
| Receivables | 12.3 | 92.87 | 71.18 | 47.46 | 108.3 | Upgrade
|
| Inventory | 194.27 | 246.9 | 106.86 | 50.26 | - | Upgrade
|
| Prepaid Expenses | 81.5 | 8.07 | 16.89 | 13 | 2.31 | Upgrade
|
| Other Current Assets | 0.47 | 133.73 | 201.37 | 208.81 | 155.21 | Upgrade
|
| Total Current Assets | 375.13 | 605.9 | 461.69 | 513.52 | 561.01 | Upgrade
|
| Property, Plant & Equipment | 0.04 | 64.9 | 88.2 | 71.05 | 73.8 | Upgrade
|
| Long-Term Deferred Charges | 296.46 | 167.69 | 99.67 | 102 | 49.67 | Upgrade
|
| Other Long-Term Assets | - | 3.95 | 3.95 | 3.95 | 3.95 | Upgrade
|
| Total Assets | 671.62 | 842.43 | 653.51 | 690.52 | 688.43 | Upgrade
|
| Accounts Payable | 8.96 | 242.57 | 30.97 | 23.3 | 41.39 | Upgrade
|
| Accrued Expenses | 36.19 | 41.19 | 140.89 | 66.48 | 65.76 | Upgrade
|
| Current Portion of Long-Term Debt | - | 82.5 | 62.5 | - | - | Upgrade
|
| Current Portion of Leases | - | 13.27 | 13.37 | 9.16 | 7.91 | Upgrade
|
| Current Unearned Revenue | - | 147.26 | 75.41 | 136.06 | 95.39 | Upgrade
|
| Other Current Liabilities | 7.52 | 11.15 | 3.42 | 1.56 | 9.22 | Upgrade
|
| Total Current Liabilities | 52.66 | 537.94 | 326.56 | 236.57 | 219.67 | Upgrade
|
| Long-Term Debt | 58.31 | 66.37 | 112.9 | - | - | Upgrade
|
| Long-Term Leases | - | 29.58 | 42.71 | 29.06 | 36.48 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | - | 0.54 | Upgrade
|
| Other Long-Term Liabilities | - | -0 | 0.01 | - | - | Upgrade
|
| Total Liabilities | 110.97 | 633.89 | 482.17 | 265.63 | 256.69 | Upgrade
|
| Common Stock | 2.06 | 343.5 | 6.68 | 6.17 | 5.61 | Upgrade
|
| Additional Paid-In Capital | 1,386 | 1,395 | 1,429 | 1,294 | 1,134 | Upgrade
|
| Retained Earnings | -837.61 | -1,540 | -1,274 | -885.83 | -713.31 | Upgrade
|
| Comprehensive Income & Other | 10.11 | 10.23 | 10.12 | 10.32 | 5.16 | Upgrade
|
| Shareholders' Equity | 560.65 | 208.54 | 171.34 | 424.89 | 431.74 | Upgrade
|
| Total Liabilities & Equity | 671.62 | 842.43 | 653.51 | 690.52 | 688.43 | Upgrade
|
| Total Debt | 58.31 | 191.72 | 231.48 | 38.22 | 44.38 | Upgrade
|
| Net Cash (Debt) | 28.28 | -67.39 | -166.08 | 155.77 | 250.8 | Upgrade
|
| Net Cash Growth | - | - | - | -37.89% | 5.88% | Upgrade
|
| Net Cash Per Share | 2.32 | -6.85 | -723.19 | 761.51 | 1328.76 | Upgrade
|
| Filing Date Shares Outstanding | 20.61 | 12.24 | 0.24 | 0.22 | 0.2 | Upgrade
|
| Total Common Shares Outstanding | 20.61 | 12.24 | 0.24 | 0.22 | 0.2 | Upgrade
|
| Working Capital | 322.47 | 67.96 | 135.14 | 276.96 | 341.34 | Upgrade
|
| Book Value Per Share | 27.21 | 17.04 | 718.44 | 1930.89 | 2155.27 | Upgrade
|
| Tangible Book Value | 560.65 | 208.54 | 171.34 | 424.89 | 431.74 | Upgrade
|
| Tangible Book Value Per Share | 27.21 | 17.04 | 718.44 | 1930.89 | 2155.27 | Upgrade
|
| Machinery | - | 62.43 | 61.93 | - | 43.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.